NASDAQ: CALCCalcimedica Inc Stock
$2.30+0.28 (+13.86%)
Updated Sep 9, 2026
CALC Price
$2.30
Fair Value Price
$0.00
Market Cap
$15.67M
52 Week Low
$1.91
52 Week High
$36.00
P/E
-0.34x
P/B
2.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.54
Operating Cash Flow
-$19M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CALC Overview
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company developing treatments of retina and optic nerve diseases. Known as Graybug LLC until 2016, Graybug Vision was incorporated in 2011 and is based in Redwood City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CALC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CALC
Ranked#386 of 461
Ranked#386 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.05 | A | |
| $115.70 | A | |
| $6.80 | A |
Be the first to know about important CALC news, forecast changes, insider trades & much more!
CALC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CALC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CALC ($2.30) is overvalued by 378,482.22% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CALC ($2.30) is not significantly undervalued (378,482.22%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CALC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CALC due diligence checks available for Premium users.
Valuation
CALC fair value
Fair Value of CALC stock based on Discounted Cash Flow (DCF)
Price
$2.30
Fair Value
$0.00
Overvalued by
379,307.01%
CALC ($2.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CALC ($2.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CALC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CALC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
9.33x
Market
40.8x
CALC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.84x
Industry
5.42x
CALC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CALC's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.7M
Profit Margin
0%
CALC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.5M
Liabilities
$14.0M
Debt to equity
2.54
CALC's short-term assets ($19.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CALC's short-term assets ($19.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CALC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CALC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$42.0k
Financing
$15.0M
CALC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CALC vs Biotech Stocks
Calcimedica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.